Autolus Therapeutics plc American Depositary Receipt (AUTL)
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Autolus Therapeutics plc ( AUTL ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Amanda Cray Christian Itin - CEO & Director Robert Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Goonewardene - Truist Securities, Inc., Research Division Gil Blum - Needham & Company, LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Madeleine Stone - William Blair & Company L.L.C., Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good day.
Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable
I remain bullish on Autolus Therapeutics as they advance their CAR T-cell therapy, obe-cel, in a competitive leukemia market. Obe-cel shows durable benefits, with 38% of responders at 33 months needing no further therapy, suggesting potential as a definitive treatment. Recent EU approval and expansion into new indications like non-Hodgkin lymphoma and autoimmune diseases strengthen AUTL's market position.
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Amanda Cray - Corporate Participant Christian Martin Itin - CEO & Director Robert F. Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Sarith Goonewardene - Truist Securities, Inc., Research Division Dingding Shi - Jefferies LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division James John Shin - Deutsche Bank AG, Research Division Matthew Christopher Phipps - William Blair & Company L.L.C.
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Autolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenues may be no more than $200 - $300m, but the drug's launch has been successful, with $9m earned in Q1 2025. Autolus plans to share more data from its FELIX study imminently, which could open up approval shots in other liquid cancer indications.
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants James Shin – Deutsche Bank Matthew Phipps – William Blair Karina Rabayeva – Truist Gil Blum – Needham & Company Yanan Zhu – Wells Fargo Operator Good day, and thank you for standing by. Welcome to the Autolus First Quarter 2025 Financial Results Conference Call.
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jacob Mekhael - KBC Securities Simon Baker - Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Conference Call Participants James Shin - Deutsche Bank Matthew Phipps - William Blair Sebastiaan van der Schoot - VLK Hanze Zu - Jefferies Gil Blum - Needham & Company Jacob Mekhael - KBC Securities Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Third Quarter 2024 Financial Results and Business Updates. At this time, all participants are in a listen-only mode.
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights.
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – William Blair Yanan Zhu – Wells Fargo Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Second Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2024 Earnings Conference Call May 17, 2024 8:30 AM ET Company Participants Olivia Manser – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Kelly Shi – Jefferies James Shin – Deutsche Bank Asthika Goonewardene – Truist Matthew Phipps – Blair Gil Blum – Needham & Company Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics' Call to discuss its First Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.
